Drug Trial Radar · NCT06239298
A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor
Last checked: Nov 19, 2026Latest source record: Jun 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
130
Planned (sponsor's estimate)
Start
May 10, 2024
Primary completion
Mar 2026
Study completion May 2026
Sponsor
- Lead sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Multi-center, Open-labe, Phase I/II Study to evaluate the safety and tolerability of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor.
Conditions
- Solid Tumor
Interventions
ZG005 Powder for InjectionDrug
intravenous infusion(IV), once every 3 weeks
Donafenib Tosilate TabletsDrug
The dose groups of Donafenib for dose-exploration stage are set as 0.2g BID, 0.1g BID, and 0.1g QD, oral administration.The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Up to 2 years
- Dose Limiting Toxicity (DLT)Time frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Army Medical University
Chongqing, Chongqing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.